BREAKING
Home » Archive by Category "Vaccines" (Page 3)

NIH: Investigational COVID-19 vaccine generally well tolerated and prompted neutralizing antibody activity

By

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody...

Universal Coronavirus & Influenza Vaccines: Osivax secures funding

By

Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza. The Company’s proprietary oligoDOM®...

Anthrax: Single dose intranasal vaccine, NasoShield, Phase 1b clinical trial

By

Altimmune, Inc. announced today dosing of the first patient in the Company’s Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. “NasoShield is the only single...

Research shows 1-in-15 hesitant about routine childhood vaccines and almost 1-in-4 hesitant about influenza vaccines

By

A national study measuring parental attitudes toward vaccinations found 6.1% were hesitant about routine childhood immunizations while nearly 26% were hesitant about the influenza vaccine. “Our...

Equine encephalitis vaccine: Bavarian Nordic announces topline results from the the first-in-human trial

By

Bavarian Nordic A/S announced today topline results from the the first-in-human trial of MVA-BN® WEV, a prophylactic vaccine candidate against three equine encephalitis viruses (western, eastern and...

Chikungunya vaccine: The Lancet provides a detailed analysis of final Phase 1 results

By

Valneva SE, a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The...

COVID-19: ImmunityBio vaccine part of ‘Operation Warp Speed’

By

Clinical-stage, natural killer cell-based therapeutics company, NantKwest and  ImmunityBio, a privately-held immunotherapy company announced ImmunityBio has been selected to participate in Operation Warp...

COVID-19

COVID-19 vaccine: Novavax initiates Phase 1/2 Clinical Trial

By

Biotechnology company, Novavax, Inc. today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein...

Coronavirus vaccine: Moderna announces positive interim Phase 1 data

By

Clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, Inc.,  announced Monday positive interim clinical data of mRNA-1273, its vaccine candidate against...

Marburg Virus Disease

Ebola Sudan and Marburg Vaccines: Sabin Vaccine Institute gets $20 million from BARDA for further development

By

The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for...